Motoneurone Disease Stroke Peripheral Neuropathy Multiple Sclerosis Lennox-Gastaut Absence Epilepsy Eye Diseases
Drug Platform Discovery Pharmacokinetics Pharmacodynamic Clinical Studies Publications
Our Mission Directors
Press Releases


Curonz is a clinical stage biotechnology company with a drug portfolio covering the peptide family, Neural Regeneration Peptides (NRPs), which were discovered by Curonz's founding Director, Dr Frank Sieg and where precursor compounds to our clinical molecule NRP2945 were first patented back in 2001. We currently have offices in NZ and Australia.

We have completed Clinical Phase I in Australia for our lead drug candidate NRP2945 with 49 healthy volunteers.  Currently, we have received human ethical approval for studying NRP2945 in a small Phase II proof of concept study in adults with typical absence epilepsy which is due to start late 2018. By mid 2019, we intend to file an IND with the FDA for the initiation of a clinical phase II study in Lennox-Gastaut Syndrome children.

Curonz aims to licensing the platform of compounds or reach other commercial arrangements to provide a clear pathway forward to bring this promising therapeutic treatment as quickly as possible to patients.

Business Overview

  • Drug candidates: Neural Regeneration Peptides (NRPs) of synthetic origin, classified as NCEsdrug candidate
  • In 2017, the clinical compound NRP2945 completed a Clinical Phase I study (healthy volunteers) in Melbourne and all associated reports have been completed
  • In late 2018, we are running a small proof of concept study in 5 patients with typical absence epilepsy
  • In early to mid 2019, once the IND is approved NRP2945 will be studied for refractory epilepsy in children diagnosed with Lennox-Gastaut Syndrome (LGS) - Phase II clincial study
  • Internationally granted patent claims for NRP2945 and other NRPs directed to neural regeneration and protection regarding the central nervous system
  • In excess of US $15 million invested in the development of these class of compounds to date
  • Unique mechanism of action which produces both regeneration of CNS tissue and anti-inflammatory effects
  • Support from the General US-based Fast Forward fund (MS society), from the New Zealand government and private equity investment up to IND
  • Potential for Orphan drug designation and breakthrough status for NRPs

These exciting peptides have proven efficacy within various neurodegenerative animal disease models indicating significant future therapeutic effects for several human central neural system diseases which currently have few or no treatments and potentially other applications. 

Our drug candidate has huge potential, however, we need a pharma partner or clinical phase II investment to enable us to achieve our technical and commercial goals.

Go To:

Contact Us About Us Research Target Diseases Investors